登录新浪财经APP 搜索【信披】查看更多考评等级 ● 减持计划的主要内容：因个人资金需求，焦承尧先生、付奇先生、张海斌先生拟自本减持计划公告披 露之日起15个交易日后的3个月内（有关法律、行政法规、规范性文件规定的不得减持股份的期间除 外），通过上海证券交易所证券交易系统以集中竞价交易方式减持公司股份。焦承尧先生拟减持不超过 1,056,700股，付奇先生拟减持不超过158,900股，张海斌先生拟减持不超过211,500股。上述减持主体减 持股数均不超过其本人上年末持股总数的25%，减持价格将按照减持实施时的市场价格确定。 一、减持主体的基本情况 ■ 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担法律责任。 说明："其他方式取得"为公司上市后资本公积转增股本取得股份。 重要内容提示： ■ ● 董事、高级管理人员持股的基本情况：截至本公告披露日，中创智领（郑州）工业技术集团股份有限 公司（以下简称"公司"）董事长焦承尧先生持有公司A股股份4,226,964股，占公司当前总股本的 0.2368%；副总经理付奇先生持有公司A股股份6 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 公告送出日期：2025年12月22日 1 公告基本信息 ■ 注：①2025年12月25日为境外主要投资场所节假日。 ②根据基金境外主要投资场所节假日休市安排，为满足投资者的投资需求，自2025年12月26日起本基金 恢复办理申购、赎回业务，届时本公司将不再另行公告。 ③场内简称：标普ETF 2其他需要提示的事项 2.1投资者在2025年12月25日仍可进行本基金的二级市场交易。 2.2本基金自2025年12月26日起恢复办理申购、赎回业务，届时本公司将不再另行公告。本公告为因境 外主要投资场所节假日休市安排暂停和后续恢复相关业务的说明，本基金如因其他原因暂停/恢复申 购、赎回业务，具体业务办理以相关公告为准。 （一）会议召开方式：通讯方式。 （二）表决票收取时间：2025年12月25日至2026年1月22日17:00（以收到表决票的时间为准） 2.3若基金境外主要投资场所节假日休市安排、深圳证券交易所状况等发生变化，或根据法律法规、基 金合同等规定需要调整上述事项的，或中国证监会、证券交易所发布新的节假日放假和休市安排影响本 基金申赎等业务办理的，本公司将及时 ...

Investment Overview - The company plans to invest 30 million RMB in Beijing Zhongke Hongtai Medical Technology Co., Ltd., acquiring a 10% stake in the company [1][2] - The investment is part of the company's strategy to optimize its industrial structure and seek new growth opportunities in the medical robotics sector [2] Investment Details - The investment will consist of 195.86895 million RMB for subscribing to the new registered capital and 28.0413105 million RMB to be allocated to capital reserves [2] - The investment has been approved internally and does not require further approval from the board or shareholders [3][4] Target Company Information - Zhongke Hongtai specializes in the research, production, and sales of medical robotics technology and systems, founded by a team of experts from the Chinese Academy of Sciences [5] - The company has over 100 independent intellectual property rights and is involved in significant national projects, including the "14th Five-Year" national key research and development plan [5][6] Product and Market Position - The company's flagship product, a multi-channel vascular interventional surgical robot, has unique advantages such as bionic design and dual-channel operation [6] - The product is currently undergoing clinical trials, with 16 trials completed as of the announcement date [6] Financial and Operational Impact - The investment aims to enhance the company's profitability and overall competitiveness while not affecting its daily operations or financial reporting [16] - The funds will be used exclusively for technology research and development, market promotion, and daily operations, not for debt repayment or unrelated expenditures [12]

Core Viewpoint - The company plans to acquire a 15.7147% stake in Zhejiang Noah Fluorochemical Co., Ltd. for a total consideration of approximately 256.94 million yuan, positioning itself as the second-largest shareholder in the company, with a shareholding difference of 0.1415% from the largest shareholder [1][3][5]. Transaction Overview - The transaction involves the acquisition of shares from six shareholders, including Shaoxing Shangyu Longcang Equity Investment Partnership [1][3]. - The transaction has been approved by the company's board of directors and does not require shareholder approval [1][5]. - The transaction is not classified as a related party transaction or a major asset restructuring under relevant regulations [1][5]. Target Company Information - Zhejiang Noah Fluorochemical is a high-tech enterprise specializing in the research, development, manufacturing, and sales of fluorinated electronic chemicals, with key products including fluorinated cooling liquids and high-end electronic cleaning agents [3][8]. - The company has established a production capacity of 5,000 tons of fluorinated liquids, ranking among the top in the domestic market for immersion cooling [3][8]. Strategic Intent - The acquisition aims to leverage the company's upstream fluorite resources and core advantages in basic fluorochemical products to expand into the high-growth fine fluorochemical sector, aligning with the company's "resource + technology" dual-driven strategy [5][17]. - The transaction is expected to enhance the company's vertical integration and deepen its value chain through strategic investments in high-value fluorinated material projects [10][17]. Financial Aspects - The transaction price is based on market negotiations and reflects the target company's current and future profit expectations, with a post-investment valuation of 1.635 billion yuan [10][11]. - The target company reported revenues of approximately 51 million yuan and a net profit of about 6.41 million yuan for the first ten months of 2025, indicating a 38.64% increase in net profit compared to the previous year [11]. Payment Structure - The payment for the acquisition will be made in two installments, with the first payment of approximately 128.47 million yuan due within ten working days after the fulfillment of certain conditions [12][13].

Core Viewpoint - Shenzhen Zhaowei Electromechanical Co., Ltd. is in the process of applying for an overseas listing of foreign shares (H-shares) on the Main Board of the Hong Kong Stock Exchange [1][2] Group 1 - The company submitted its application for the issuance and listing on June 18, 2025, and updated the application on December 19, 2025 [1][3] - The application materials were published on the Hong Kong Stock Exchange website and are subject to updates and revisions as required by the Hong Kong Securities and Futures Commission and the Hong Kong Stock Exchange [1][2] - The subscription for this issuance is limited to qualified overseas investors and domestic qualified investors who are authorized to conduct overseas securities investments under Chinese laws [2] Group 2 - The company’s issuance and listing are still subject to approval from the Hong Kong Securities and Futures Commission and the Hong Kong Stock Exchange, indicating uncertainty in the process [3] - The company will fulfill its information disclosure obligations based on the progress of this matter [3]

登录新浪财经APP 搜索【信披】查看更多考评等级 1、南方浩信积极3个月持有期混合型基金中基金（FOF）（以下简称"本基金"）的发售已获中国证监会 2025年11月6日证监许可[2025]2487号文注册。 2、南方浩信积极3个月持有期混合型基金中基金（FOF）是契约型开放式基金。 3、本基金的管理人和登记机构为南方基金管理股份有限公司（以下简称"本公司"），基金托管人为南 京银行股份有限公司（以下简称"南京银行"）。 4、本基金募集期自2026年1月19日至2026年2月6日，通过基金管理人指定的销售机构公开发售。 5、本基金的发售对象为符合法律法规规定的可投资于证券投资基金的个人投资者、机构投资者、合格 境外投资者以及法律法规或中国证监会允许购买证券投资基金的其他投资人。 6、本基金首次认购和追加认购最低金额均为人民币1元（含认购费），具体认购金额以各基金销售机构 的公告为准。 7、有效认购款项在募集期间产生的利息将折算为基金份额归基金份额持有人所有，其中利息转份额的 数额以登记机构的记录为准。 8、基金投资人在募集期内可多次认购，认购一经确认不得撤销。基金销售机构对认购申请的受理并不 代表该申请一定成功 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及全体董事、监事、高级管理人员保证信息披露的内容真实、准确、完整、及时，没有虚假记 载、误导性陈述或重大遗漏。 经上海证券交易所（以下简称"上交所"）审核同意，江苏锡华新能源科技股份有限公司（以下简称"锡 华科技""发行人"或"公司"）人民币普通股股票将于２０２５年１２月２３日在上交所主板上市，上市 公告书全文和首次公开发行股票的招股说明书全文披露于上交所网站（ｗｗｗ．ｓｓｅ．ｃｏｍ．ｃ ｎ）和符合中国证券监督管理委员会规定条件的网站（中国证券网，ｗｗｗ．ｃｎｓｔｏｃｋ．ｃｏ ｍ；中证网，ｗｗｗ．ｃｓ．ｃｏｍ．ｃｎ；证券时报网，ｗｗｗ．ｓｔｃｎ．ｃｏｍ；证券日报网， ｗｗｗ．ｚｑｒｂ．ｃｎ；经济参考网，网址ｗｗｗ．ｊｊｃｋｂ．ｃｎ；中国金融新闻网，网址ｗｗ ｗ．ｆｉｎａｎｃｉａｌｎｅｗｓ．ｃｏｍ．ｃｎ；中国日报网，网址ｗｗｗ．ｃｈｉｎａｄａｉｌ ｙ．ｃｏｍ．ｃｎ），并置备于发行人、上交所、本次发行保荐人（联席主承销商）国泰海通证券股份 有限公司和联席主承销商西南证券股份有限公司的住所，供投资者查阅。 本公司提醒广大投资者注意首次公开发行股票（以下简称"新 ...

中国证券报记者深入调研，对话多家头部基金投顾机构，梳理出行业共识：告别简单"股债搭配"，拥抱 多元、动态、全球化的科学配置；看准"科技+周期+消费"三大主线，并用"核心-卫星"策略严阵以待。 在他们眼中，2026年，没有"躺赢"的赛道，只有"精耕细作"后的收获。 在市场还在为年末涨跌反复纠结时，专业的 "基金买手" 已率先锚定2026年的投资机遇，紧锣密鼓地推 进三件大事：调仓、定策、选方向。 岁末调仓进行时 当2025年交易进入倒计时，专业的"基金买手"——基金投顾机构们，正进入一年中最繁忙、也最关键的 布局时节。 近日，记者实地走访多家头部基金投顾机构，从他们紧凑的日程、屏幕上不断刷新的数据和专注的讨论 中，深切地感受到岁末的调仓，绝非追逐短期排名的博弈，而是一场着眼于2026年，对投资组合进 行"精耕细作"的结构性优化。 在近期部分投顾组合的实际操作中，"结构性优化"的思路清晰可见。11月25日，华夏权益优选组合小幅 加仓处于周期和估值低位的地产链。这一动作与华夏财富投顾团队的宏观思路一脉相承。该团队负责人 向记者表示："我们认为，2026年科技股继续一枝独秀的概率不大，需要适当布局处于周期和估值低位 ...

12月20日，由中国经济传媒协会主办，传媒茶话会、中国经济传媒协会新媒体分会承办的"2025中国经济媒体融合发展交流大会"在北京召开。会上公布 了"2025年中国经济媒体融合发展典型案例"，中国证券报推荐的《信用卡违规套现调查！拉卡拉POS机里的"假商户"》成功入选"2025中国经济媒体融合 报道典型案例"。 党的二十届三中全会后，媒体融合有了全新的战略和使命，主流媒体系统性变革成为媒体深度融合发展的新指引与新方向，标志着中国媒体融合进入新的 历史阶段。这一年，经济媒体行业深入贯彻落实党中央决策部署，持续探索媒体融合发展，新的业态、场景、案例、模式不断涌现。 融合报道典型案例紧扣国家经济发展主线，深耕宏观政策解读与民生经济热点。专家评审委员会提到，22个获评"2025中国经济媒体融合报道典型案例"的 新闻作品，综合运用多媒体手段报道，主题鲜明、内涵丰富、形式新颖，为行业在新媒体时代实现价值引领，树立了鲜活范式。 其中，中国证券报《信用卡违规套现调查！拉卡拉POS机里的"假商户"》，以暗访形式记录销售人员违规全过程，实现对POS机套现黑产的实证式揭露， 引发了社会对行业乱象的警惕，更在普及金融知识、推动行业规范 ...

Core Viewpoint - Bohai Chemical announced the termination of its major asset restructuring plan, which involved the sale of 100% equity in Bohai Petrochemical and the acquisition of control over Taida New Materials, due to a lack of consensus on key terms among the parties involved [1][2] Group 1: Restructuring Details - The restructuring plan began on December 5, 2025, with Bohai Chemical signing a letter of intent with its controlling shareholder Bohua Group and Taida New Materials [2] - The transaction consisted of two parts: selling 100% equity of Bohai Petrochemical to Bohua Group and acquiring control of Taida New Materials through share issuance and cash payments [2] - The decision to terminate the restructuring was made to protect the interests of the company and its investors, as the parties could not reach an agreement on core terms [2] Group 2: Financial Performance and Challenges - Bohai Chemical has been facing dual pressure from supply and demand, leading to continuous losses in its propane dehydrogenation (PDH) business [4] - The company reported a revenue of 2.809 billion yuan for the first three quarters of 2025, a year-on-year decrease of 16.82%, with a net loss of 579 million yuan, which has worsened compared to the previous year [4] - The PDH industry is experiencing structural overcapacity, resulting in ongoing profitability issues for Bohai Chemical [4]